Oglesby A, et al. Patient-reported outcomes after switching to a two-drug regimen of dolutegravir + rilpivirine: Week 100 results from the SWORD-1 and SWORD-2 studies. Abstract P101. HIV/Drug Therapy Glasgow 2018.
Hiv en COVID-19: risicofactoren voor ernstige ziekte
feb 2021 | HIV, Virale infecties